pharmaphorum

AUGUST 25, 2022

Tecvayli (teclistamab) has been approved by the European Commission for adults with the blood cancer whose disease has progressed have after at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, said J&J. and 18,3 months, respectively.

Antibody 98

Antibody Marketing Drugs Medicine 98

pharmaphorum

JULY 25, 2022

Tecvayli (teclistamab) is an off-the-shelf bispecific antibody targeting both BCMA and CD3 which is also under review at the FDA and if approved will slot into J&J’s myeloma therapy portfolio alongside Darzalex (daratumumab) – an antibody directed at CD38 – and BCMA-targeted CAR-T therapy Carvykti (ciltacabtagene autoleucel). .”

Antibody 52

Antibody Medicine Drugs Trials 52

pharmaphorum

MARCH 27, 2022

Both CAR-Ts are directed at BCMA, a biomarker for multiple myeloma also targeted by GlaxoSmithKline’s approved antibody-drug conjugate Blenrep (belantamab mafodotin) and J&J’s experimental bispecific antibody teclistamab, which was submitted for approval in Europe last month.

Antibody 98

Antibody Clinical Trials Clinical Trials Sales 98

XTalks

DECEMBER 21, 2022

The multi-million-dollar price tags are largely attributable to the high R&D and manufacturing costs associated with making a gene therapy, as the raw materials for producing the therapy can be expensive. Currently, CSL Behring’s one-dose Hemophilia B gene therapy Hemgenix holds the title at $3.5 million for a single infusion.

Life Science 52

Life Science Gene Therapy Gene Clinical Trials 52